营养健康品
Search documents
仙乐健康(300791):2025年三季报点评:收入提速,更待来年
Huachuang Securities· 2025-10-29 03:46
Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 32.5 yuan [2][8]. Core Insights - The company reported a revenue of 3.291 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 7.96%. The net profit attributable to shareholders was 260 million yuan, up 8.53% year-on-year [2][8]. - In Q3 alone, the company achieved a revenue of 1.25 billion yuan, marking an 18.11% increase year-on-year, with a net profit of 99 million yuan, up 16.2% year-on-year [2][8]. - The report highlights significant revenue growth driven by improved sales structure and new customer orders, particularly in the Chinese market, which saw a revenue increase of over 20% [8][9]. Financial Performance Summary - The total revenue forecast for 2024 is 4.211 billion yuan, with expected growth rates of 17.6% in 2024, 8.9% in 2025, and 11.0% in 2026 [4][13]. - The net profit forecast for 2024 is 325 million yuan, with growth rates of 15.7% in 2024, 8.3% in 2025, and 28.1% in 2026 [4][13]. - The earnings per share (EPS) is projected to be 1.06 yuan in 2024, increasing to 1.15 yuan in 2025 and 1.47 yuan in 2026 [4][13]. Market Dynamics - The report notes that the company is experiencing a positive trend in multiple markets, with significant contributions from the Chinese, American, and European regions [8][9]. - The sales structure has improved, leading to a gross margin increase to 30.76% in Q3, up 1.12 percentage points year-on-year [8][9]. - The company is expected to continue benefiting from digital system enhancements and operational efficiencies, which are anticipated to support revenue growth and improve profitability [8][9].